# Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet Versus Cataflam® 50 Coated Tablet

> **NCT05082662** · PHASE1,PHASE2 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 36 (actual)

## Conditions studied

- Non-steroidal Anti-inflammatory (NSAID)
- Analgesic
- Antipyretic

## Interventions

- **DRUG:** Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)
- **DRUG:** Cataflam® 50 coated tablet

## Key facts

- **NCT ID:** NCT05082662
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-25
- **Primary completion:** 2020-09-16
- **Final completion:** 2020-09-16
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082662, "Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet Versus Cataflam® 50 Coated Tablet". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05082662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*